Increase the testosterone dose
Your patient's testosterone level of 264 ng/dL on 100 mg weekly is suboptimal and warrants a dose increase to achieve target levels in the mid-normal range (400-700 ng/dL).
Recommended Dosing Adjustment
Increase to 150 mg intramuscular weekly or switch to 200 mg every 2 weeks. The FDA label indicates that replacement dosing ranges from 50-400 mg every 2-4 weeks, with dose adjustments based on patient response 1. However, the weekly regimen provides more stable levels and better outcomes.
Why This Dose Increase is Necessary
- A testosterone level of 264 ng/dL falls below the therapeutic target range. Most guidelines define hypogonadism as total testosterone ≤300 ng/dL 2, and your patient is barely above this threshold despite treatment
- Research demonstrates that baseline testosterone <264 ng/dL is associated with greater improvements in fat-free mass with therapy, but metabolic benefits (HbA1c, fasting glucose, LDL, leptin) are actually superior when levels reach ≥264 ng/dL 3
- The dose-response relationship for testosterone is linear for muscle mass, strength, hemoglobin, and metabolic parameters 4, meaning higher physiologic doses produce better outcomes without adverse cardiovascular effects
Specific Dosing Options
Option 1 (Preferred): 150 mg IM weekly
- Provides more stable testosterone levels throughout the week
- Reduces peak-to-trough fluctuations
- Lower risk of erythrocytosis compared to biweekly dosing 5
Option 2: 200 mg IM every 2 weeks
- Standard FDA-approved regimen 1
- Historical data shows this effectively suppresses LH to normal and maintains testosterone in therapeutic range 6
- However, carries 8% risk of hematocrit >54% versus only 1% with weekly dosing 5
Monitoring Requirements
After dose adjustment, recheck testosterone levels in 6-8 weeks:
- Draw blood at mid-cycle (3-4 days after injection for weekly dosing, or 7 days after injection for biweekly dosing)
- Target: 400-700 ng/dL mid-cycle level
- Also monitor: hematocrit (keep <54%), PSA, lipid panel
Critical Safety Consideration
The primary dose-limiting adverse effect is polycythemia. Men receiving 100 mg weekly have significantly lower rates of problematic hematocrit elevation (1%) compared to 200 mg biweekly (8%) 5. The 2004 NEJM guideline emphasizes that hematocrit elevation above normal range may have grave consequences in elderly men due to increased blood viscosity aggravating vascular disease 7.
If hematocrit rises above 54%: reduce dose, increase injection frequency, or consider therapeutic phlebotomy.
What NOT to Do
- Don't continue current dose hoping levels will improve—they won't without intervention
- Don't increase to supraphysiologic doses (>600 mg/week equivalent)—this increases HDL reduction risk without additional benefit 7
- Don't use 400 mg every 4 weeks—this regimen fails to adequately suppress LH and produces suboptimal testosterone levels 6
The evidence strongly supports dose escalation in your patient, with weekly dosing offering the best balance of efficacy and safety 5, 6.